ATE241358T1 - Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen - Google Patents

Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen

Info

Publication number
ATE241358T1
ATE241358T1 AT98905121T AT98905121T ATE241358T1 AT E241358 T1 ATE241358 T1 AT E241358T1 AT 98905121 T AT98905121 T AT 98905121T AT 98905121 T AT98905121 T AT 98905121T AT E241358 T1 ATE241358 T1 AT E241358T1
Authority
AT
Austria
Prior art keywords
cholinesterase inhibitors
concentration disorders
treat concentration
treat
disorders
Prior art date
Application number
AT98905121T
Other languages
German (de)
English (en)
Inventor
Sharon L Rogers
Lawrence T Friedhoff
Paul J Tiseo
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE241358T1 publication Critical patent/ATE241358T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT98905121T 1997-03-03 1998-03-03 Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen ATE241358T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3983297P 1997-03-03 1997-03-03
PCT/IB1998/000508 WO1998039000A1 (en) 1997-03-03 1998-03-03 Use of cholinesterase inhibitors to treat disorders of attention

Publications (1)

Publication Number Publication Date
ATE241358T1 true ATE241358T1 (de) 2003-06-15

Family

ID=21907565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98905121T ATE241358T1 (de) 1997-03-03 1998-03-03 Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen

Country Status (12)

Country Link
US (2) US6455544B1 (cg-RX-API-DMAC7.html)
EP (1) EP0971713B1 (cg-RX-API-DMAC7.html)
JP (1) JP4095676B2 (cg-RX-API-DMAC7.html)
AT (1) ATE241358T1 (cg-RX-API-DMAC7.html)
AU (1) AU743609B2 (cg-RX-API-DMAC7.html)
CA (1) CA2282654C (cg-RX-API-DMAC7.html)
DE (1) DE69815090T2 (cg-RX-API-DMAC7.html)
DK (1) DK0971713T3 (cg-RX-API-DMAC7.html)
ES (1) ES2200313T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ337515A (cg-RX-API-DMAC7.html)
PT (1) PT971713E (cg-RX-API-DMAC7.html)
WO (1) WO1998039000A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT971713E (pt) * 1997-03-03 2003-09-30 Eisai Co Ltd Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1764101A1 (en) * 2000-03-03 2007-03-21 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
EP2133078A1 (en) * 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
AU2003236500B9 (en) 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4845873B2 (ja) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
WO2005105742A1 (ja) * 2004-04-28 2005-11-10 Eisai R&D Management Co., Ltd. １－ベンジル－４－［（５，６－ジメトキシ－１－インダノン）－２－イル］メチルピペリジンおよびその塩酸塩の製造法
WO2006036936A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US20060079558A1 (en) * 2004-09-27 2006-04-13 Bridge Pharma. Inc. R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
AU2006209216A1 (en) 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
EP1871368B1 (en) * 2005-04-04 2011-06-08 Eisai R&D Management Co., Ltd. Dihydropyridine compounds for neurodegenerative diseases and dementia
WO2007043440A1 (ja) * 2005-10-14 2007-04-19 Eisai R & D Management Co., Ltd. １－ベンジル－４－［（５，６－ジメトキシ－１－インダノン）－２－イル］メチルピペリジンまたはその塩酸塩の製造法
EP1960357A2 (en) * 2005-11-14 2008-08-27 Medichem S.A. Synthesis and preparations of intermediates and polymorphs thereof useful for the preparation of donepezil hydrochloride
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008011161A2 (en) * 2006-07-21 2008-01-24 Bridge Pharma, Inc. Dermal anesthetic compounds
CA2671006A1 (en) * 2006-12-01 2008-06-05 Nitto Denko Corporation Method for suppressing discoloration over time of adhesive preparation containing donepezil
CN101588802A (zh) * 2006-12-01 2009-11-25 日东电工株式会社 含有稳定化的多奈哌齐的贴剂
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
JP2010524844A (ja) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 認知症のためのシンナミド化合物
KR100914691B1 (ko) * 2007-08-10 2009-08-28 주식회사유한양행 도네페질 또는 그의 제조용 중간체의 제조방법
CA2725484A1 (en) * 2008-05-30 2009-12-03 Eisai R&D Management Co., Ltd. Percutaneously absorbable preparation
CN102014905B (zh) * 2008-05-30 2012-11-14 日东电工株式会社 含有多奈哌齐的贴剂及其包装体
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2947174C (en) 2014-04-30 2023-02-28 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use
KR101732776B1 (ko) * 2014-10-08 2017-05-04 영남대학교 산학협력단 신규한 인데노 피리디니움 유도체 화합물 및 이의 제조방법
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
MXPA98000395A (es) * 1995-07-14 2005-04-29 Medeva Europ Ltd Composicion que comprende d-treo-metilfenidato y otra droga.
RU2190603C2 (ru) * 1996-06-07 2002-10-10 Эйсай Ко., Лтд. Полиморфные модификации донепезила гидрохлорида, способы их получения и способ лечения заболевания, сопровождающегося активностью ацетилхолинэстеразы
PT971713E (pt) * 1997-03-03 2003-09-30 Eisai Co Ltd Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao

Also Published As

Publication number Publication date
WO1998039000A1 (en) 1998-09-11
AU7321598A (en) 1998-09-22
CA2282654A1 (en) 1998-09-11
CA2282654C (en) 2009-02-03
US6455544B1 (en) 2002-09-24
JP4095676B2 (ja) 2008-06-04
NZ337515A (en) 2002-07-26
EP0971713A1 (en) 2000-01-19
ES2200313T3 (es) 2004-03-01
US20030055040A1 (en) 2003-03-20
PT971713E (pt) 2003-09-30
JP2001515480A (ja) 2001-09-18
US7105540B2 (en) 2006-09-12
AU743609B2 (en) 2002-01-31
DK0971713T3 (da) 2003-09-22
DE69815090D1 (de) 2003-07-03
EP0971713B1 (en) 2003-05-28
DE69815090T2 (de) 2004-02-19

Similar Documents

Publication Publication Date Title
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE324908T1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE247454T1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE271865T1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
EP1056458A4 (en) PROCESS FOR THE TREATMENT OF PAIN, ESPECIALLY CHRONIC PAIN SPECIFIC TO WOMEN
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0971713

Country of ref document: EP